Latest news with #FabianGerlinghaus
Yahoo
7 days ago
- Business
- Yahoo
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
Integrated, automated facility will unlock next-generation, commercial-scale cell therapy manufacturing in Japan IDMO Smart Factory manufacturing capabilities will accelerate patient access for CAR-T and other cell therapies in the region SOUTH SAN FRANCISCO, Calif. & TOKYO, May 29, 2025--(BUSINESS WIRE)--Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. "Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost," said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. "Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world." The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, "For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments." Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow. View source version on Contacts Cellares ContactsInvestors:ir@ Media:pr@ Sign in to access your portfolio
Business Wire
7 days ago
- Business
- Business Wire
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)-- Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. 'Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost,' said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. 'Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world.' The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, 'For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments.' Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow.
Yahoo
10-04-2025
- Business
- Yahoo
Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors
Strategic collaboration aims to facilitate the manufacturing of UW–Madison's internally developed CAR-T investigational therapy Partnership seeks to address cell therapy manufacturing bottlenecks and accelerate development towards clinical trials Clinical scale manufacturing of cell therapy assets provides latest validation of Cell Shuttle's ability to empower partners to seamlessly scale production SAN FRANCISCO & MADISON, Wis., April 10, 2025--(BUSINESS WIRE)--Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO), has announced a strategic collaboration with the University of Wisconsin School of Medicine and Public Health to automate the manufacturing of a CRISPR-edited GD2 CAR-T investigational therapy. Cellares' Cell Shuttle™ supports early-phase biotechnology and academic cell therapy developers by providing an integrated, automated solution enabling immediate economies of scale and up to 50% lower batch prices compared to conventional CDMOs. As cell therapy assets mature, the platform ensures a seamless transition from clinical development to commercial-scale manufacturing, eliminating the need for costly process redesigns and multiple technology transfers and accelerating time-to-market for innovative therapies. The collaboration highlights Cellares' commitment to empowering principal investigators and researchers in academic institutions by providing access to an automated, reproducible, and scalable manufacturing platform at the earliest stages of clinical development. By leveraging the Cell Shuttle's ability to simultaneously manufacture multiple cell therapy products in parallel, this partnership overcomes longstanding manufacturing bottlenecks caused by limited manufacturing capacity. This approach shortens the journey from proof-of-concept in the lab to an investigational therapy suitable for clinical trials, ultimately aiming to improve care for patients with solid tumors. It also demonstrates how the Cell Shuttle is an automated solution for cell therapy developers of all stages, allowing them to seamlessly scale up as their manufacturing needs evolve. "Solid tumors can be challenging to treat, and many patients have limited therapeutic options," said Fabian Gerlinghaus, Co-founder and CEO of Cellares. "By collaborating with researchers at the University of Wisconsin–Madison on their CRISPR-edited GD2 CAR-T product, we remove the manufacturing barriers that can hinder promising research. Our Cell Shuttle automates and scales production to a clinical level, which accelerates the transition from academic innovation to investigational therapy and brings hope to those who need new treatment options." By enabling the CRISPR-edited GD2 CAR-T project at University of Wisconsin–Madison to achieve clinical-scale manufacturing earlier, the partnership can help unlock potential investment into the experimental therapy and expedite its path to initial human trials. The Cell Shuttle automates key steps that traditionally slow down development, thus enabling life-saving discoveries to advance more quickly. Cellares encourages collaboration with researchers, academic institutions, and commercial partners at all stages of their projects, demonstrating its unwavering commitment to advancing the field of cell therapy and expanding patient access to next-generation treatments. For more information on the Cell Shuttle and Cellares' scalable manufacturing solutions, please visit About University of Wisconsin School of Medicine and Public Health The University of Wisconsin School of Medicine and Public Health is recognized as one of the nation's leading institutions in health sciences education, research, and service. Founded in 1907 as the medical school of the University of Wisconsin–Madison, in 2005 it became the nation's first school to integrate the disciplines of medicine and public health. With a deep commitment to a vision of healthy people and healthy communities, we translate discovery into application and interconnect clinical care, education and research. The school employs more than 5,400 faculty and staff and provides educational opportunities for nearly 2,400 students and postgraduate trainees. Grants awarded to School of Medicine and Public Health principal investigators in fiscal year 2023 totaled $641 million in federal and non-federal awards. Some of the nation's leading researchers, educators, and clinicians are among the faculty, including several National Medal of Science recipients and National Academy of Science honorees. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. While the Cell Shuttle™ automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and batch release QC, addressing both manufacturing and QC bottlenecks. Cell Shuttles and Cell Qs will be deployed in Cellares' IDMO Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as conventional CDMOs with the same facility size and number of employees. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development, scale-out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit View source version on Contacts Cellares Contacts Investors:ir@ Media:pr@
